ライフサイエンスコーパス: somnolence

1 sidone were nausea, headache, akathisia, and somnolence.

2 , activated partial thromboplastin time, and somnolence.

3 he control and AgRP KO mice, probably due to somnolence.

4 e unpleasant taste, headache, dry mouth, and somnolence.

5 se events were asthenia, anorexia, pain, and somnolence.

6 The dose-limiting toxicity was somnolence.

7 vent reported among risperidone patients was somnolence.

8 ring risperidone treatment were headache and somnolence.

9 pine were dry mouth, increased appetite, and somnolence.

10 f mental status, respiratory depression, and somnolence.

11 derate constipation, weakness or fatigue, or somnolence.

12 ommon treatment-emergent adverse events were somnolence (10.0%), akathisia (7.7%), and sedation (7.7%

13 d vasodilation (63%), paresthesia (86%), and somnolence (17%).

14 s 4 [4.9%] in the control group; P<.001) and somnolence (19 [23%] in the gabapentin group vs 5 [6%] i

15 of Parkinson's disease (22 [11%] vs 4 [9%]), somnolence (20 [10%] vs 3 [6%]), dyskinesia (18 [9%] vs

16 and also experienced more treatment-emergent somnolence (21 patients [38.2%] vs 5 [8.3% ], respective

17 The most common adverse events reported were somnolence (33%), headache (33%), rhinitis (28%), and we

18 alopram (P < .05 vs placebo) were fatigue or somnolence (35 patients [41.1%]), sleep disturbance (12

19 mong patients receiving thalidomide included somnolence (4 patients), rash (2 patients), and peripher

20 recipients vs. 14.5% of placebo recipients), somnolence (5.1% vs. 1.5%), and dry mouth (5.1% vs. 0.8%

21 sidone and placebo groups, respectively) and somnolence (5.5% and 1.0%).

22 s (9%), leukopenia (7%), hyperglycemia (7%), somnolence (6%), thrombocytopenia (5%), and depression (

23 spectively, were tremor (13.9%, 5.0%, 7.5%), somnolence (8.9%, 11.9%, 1.3%), insomnia (10.1%, 9.4%, 1

24 in (15.3% vs 2.3%), fatigue (13.7% vs 0.0%), somnolence (9.9% vs 1.5%), and hypersalivation (9.9% vs

25 t in the augment-aripiprazole group included somnolence, akathisia, and weight gain.

26 n (grade 4), raised bilirubin, vomiting, and somnolence (all grade 3).

27 Adverse effects included somnolence and dizziness with TCAs, SNRIs, and anticonvu

28 dose-related, and evolved from complaints of somnolence and dizziness, to more pronounced signs and s

29 s reported for pregabalin and lorazepam were somnolence and dizziness.

30 scriminatory for the presentation of daytime somnolence and gait ataxia.

31 patients with symptoms of excessive daytime somnolence and low AHI this may help diagnose the UARS a

32 Dose-limiting toxicities included somnolence and neuropathy.

33 isturbances, in particular excessive daytime somnolence and rapid eye movement sleep behavioural diso

34 erse effects noted with thalidomide included somnolence and rash (7 patients each), and 6 of the 29 p

35 ese studies showed adverse effects, however, somnolence and weight gain particularly being associated

36 (SICU stay </=24 hours, airway concerns, and somnolence) and disposition delays (end-of-life decision

37 cluded diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal results on liver-function tests

38 9%) and tremor, speech disorder, dizziness, somnolence, and disorientation (each 4%).

39 ven LY334370 than placebo reported asthenia, somnolence, and dizziness.

40 on adverse events were nausea, vomiting, and somnolence, and these occurred more often in the TDF gro

41 te for placebo were extrapyramidal disorder, somnolence, and tremor.

42 pophosphatemia/hypokalemia, neutropenia, and somnolence at 40 mg/m(2); and urticaria at 55 mg/m(2).

43 rder narcolepsy is associated with excessive somnolence, cataplexy and increased propensity for rapid

44 multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy.

45 Importantly, no significant somnolence, constipation, or neuropathy has been seen in

46 atients with PBC, with the degree of daytime somnolence correlating strongly with the degree of fatig

47 In 75 treated patients (213 trials), somnolence decreased using stimulants (mainly amphetamin

48 Dizziness, nausea, somnolence, diplopia, fatigue, and rash were each report

49 Somnolence, dizziness, ataxia, peripheral edema, and inf

50 Somnolence, dizziness, dry mouth, and weight gain occurr

51 frequently during olanzapine treatment were somnolence, dry mouth, increased appetite, weight gain,

52 wn side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness).

53 for the olanzapine cotherapy group included somnolence, dry mouth, weight gain, increased appetite,

54 pressed in terms that do not directly denote somnolence (e.g. 'tiredness' or 'fatigue').

55 sleep structure and cause excessive day-time somnolence (EDS).

56 correlates to symptoms of excessive daytime somnolence (EDS).

57 Both degree of daytime somnolence (ESS) and actual daytime sleep activity (acce

58 Dose-limiting reactions were neurologic (somnolence, euphoria, ataxia) and associated with the in

59 luded dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsine

60 Other serious adverse events were somnolence, fever and hypotension, and rash in three pat

61 The valproate group had higher rates of somnolence, gait disturbance, tremor, diarrhea, and weak

62 lated adverse events were dizziness, tremor, somnolence, headache, nausea, and rash.

63 1), suggesting significantly greater daytime somnolence in the patients with PBC.

64 Somnolence is the major toxicity.

65 bnormality, in the form of excessive daytime somnolence, is present in a significant proportion of pa

66 Dose-limiting toxicities were somnolence (n = 1), confusion (n = 3), and febrile neutr

67 s reported in more than 10% of patients were somnolence (n=41 [25%]), decreased appetite (n=31 [19%])

68 e brexanolone group (sinus tachycardia, n=1; somnolence, n=1) and in two patients in the placebo grou

69 Somnolence, nausea, and dizziness were the most common s

70 Reversible somnolence or stupor occurred in 3 patients at arginine

71 ed with memory difficulty, minor depression, somnolence, or headache.

72 storical descriptions of EL: sleep disorder (somnolence, sleep inversion or insomnia), lethargy, park

73 xisting agents effective at reducing daytime somnolence (such as modafinil) hold potential for the tr

74 The dose was reduced because of somnolence to 600 mg for five patients and to 400 mg for

75 enidate is used to ameliorate opioid-induced somnolence, to augment the analgesic effects of opioids,

76 quently reported for lurasidone were nausea, somnolence, tremor, akathisia, and insomnia.

77 vs three patients in the placebo group) and somnolence (two vs none).

78 rated dose-dependent increases in subjective somnolence (via Karolinska Sleepiness Scale and Visual A

79 al symptoms was similar between groups, more somnolence was observed with quetiapine (22% vs. 11%; p

80 Somnolence was significantly more common among patients

81 ed at least one adverse effect of treatment; somnolence was the most frequent.

82 Somnolence was usually mild and transient.

83 The most common adverse event, somnolence, was reported for 69 patients (13%) who recei

84 cases of dry mouth, increased appetite, and somnolence were reported with olanzapine, while more cas

85 Dizziness and somnolence were the most frequent adverse events.

86 Reversible symptoms of fatigue and somnolence were the primary toxicities, with only mild h

87 ing abnormal dreams, anxiety, dizziness, and somnolence) were significantly more common in the EFV-TD

88 iclone and zolpidem whereby DORA-22 promotes somnolence without altering the neuronal network EEG act